TP

Takeda Pharmaceutical email archive

takeda.comPharmaceuticalsJA

Explore Takeda Pharmaceutical emails, subject lines, and campaign designs. Open an example to study its layout, then remix it for your own brand in Migma.

24 emails

Takeda Announces Planned Retirement of President of Research & Development Andy Plump email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Announces Planned Retirement of President of Research & Development Andy Plump

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda’s Annual Integrated Report: Boldly reinventing for a healthier world email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda’s Annual Integrated Report: Boldly reinventing for a healthier world

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1

Takeda FY2026 Q1 Earnings Summary email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda FY2026 Q1 Earnings Summary

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

FY2026 Q1 Results Webcast email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

FY2026 Q1 Results Webcast

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda’s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies

Takeda to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda to Hold Earnings Call for Fiscal Year 2026 1st Quarter on July 30

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products

Filing of Corporate Governance Report to the Tokyo Stock Exchange email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Filing of Corporate Governance Report to the Tokyo Stock Exchange

Takeda’s Annual General Shareholders Meeting: A new era, leading with purpose and possibility email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda’s Annual General Shareholders Meeting: A new era, leading with purpose and possibility

Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees

Takeda Announces New Director Assignments and Appoints Julie Kim as President and CEO email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Announces New Director Assignments and Appoints Julie Kim as President and CEO

Takeda Announces the Publication of its Annual Report on Form 20-F for FY2025 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Announces the Publication of its Annual Report on Form 20-F for FY2025

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

New era defined by two growth horizons email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

New era defined by two growth horizons

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

Takeda revises FY2025 financial results | Exercise your vote in the Annual Shareholders Meeting email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda revises FY2025 financial results | Exercise your vote in the Annual Shareholders Meeting

Takeda Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict email from Takeda Pharmaceutical

TPTakeda Pharmaceutical

Takeda Updates FY2025 Financial Results Based on Impact of AMITIZA® Antitrust Verdict

Explore styles used by Takeda Pharmaceutical

Corporate
Light Mode
Health, Fitness & Wellness
Retention
Newsletter Subscribers
Newsletter
Consideration
Single Column
Awareness
New Product Launch
Text Heavy
Monthly Highlights